Successful Treatment of Anti-Factor H Antibody-Associated Atypical Hemolytic Uremic Syndrome

Anti-complement factor H (CFH) autoantibody (Ab)-associated atypical hemolytic uremic syndrome (aHUS) has a poor prognosis in terms of frequent relapses. Although eculizumab is an effective treatment for this type of aHUS, the method of eculizumab discontinuation is not yet established. Herein, we r...

Descripción completa

Detalles Bibliográficos
Autores principales: Kise, Tomoo, Fukuyama, Shigeru, Uehara, Masatsugu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6977382/
https://www.ncbi.nlm.nih.gov/pubmed/32015599
http://dx.doi.org/10.4103/ijn.IJN_336_18

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6977382/
https://www.ncbi.nlm.nih.gov/pubmed/32015599
http://dx.doi.org/10.4103/ijn.IJN_336_18

Ejemplares similares